or thigh; swelling of the leg, foot, and/or ankle; redness and/or noticeable discoloration; warmth. 7 The signs and symptoms of PE include short ness of breath; rapid breathing; chest pain (may be worse upon deep breath); rapid heart rate; light headedness and/or passing out. 8 About 45% to 60% of VTE cases are associ ated with hospitalization, highlighting the trou bling fact that VTE is the leading cause of pre ventable hospital death. 9 VTE adds billions to health care costs.
Nearly 1300 organizations in 98 countries were participating in the WTD in 2018, raising much needed visibility of the condition through spe cial events, educational forums, widespread me dia coverage, and social media. The Haemostasis Group of the Polish Society of Hematology and Transfusion Medicine, being a Global Partner of WTD, systematically implements initiatives dedi cated to the increase of the global as well as med ical staff awareness in the field of VTE preven tion, diagnosis, and treatment. One of these ini tiatives is an annually organized educative WTD symposium. This year, it was the 5th Conference "Venous Thromboembolism -an underestimated problem," which was held on October 13, 2018, in Warsaw. Some new data on the VTE prophylaxis and treatment have been presented by the Polish experts in these fields, for example, the draft rec ommendations for VTE prophylaxis for long dis tance (>4 hours) travelers, prepared by the Amer ican Society of Hematology/McMaster Universi ty GRADE Center.
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Much of the attention focused on direct oral anticoagulants (DOACs), which directly inhibit either thrombin (dabigatran) or factor Xa (apix aban, edoxaban, and rivaroxaban). DOACs have been approved for the treatment of VTE in gener al populations. However, in cancer patients, most guidelines continue to recommend lowmolecular weight heparin (LMWH) monotherapy for at least 3 to 6 months due to lack of cancerspe cific data regarding the use of these agents.
3,4 Cur rently, edoxaban and rivaroxaban are the only DOACs that have been compared with LMWH in randomized clinical trials in cancer populations. Nearly all studies reported lower rates of recur rent VTE for patients receiving DOACs than for those receiving LMWHs. 5, 6 However, patients receiving DOACs had a higher major bleeding rate than patients receiving LMWH. Therefore, To the Editor Venous thromboembolism (VTE) is a major contributor to the burden caused by non communicable diseases. Studies from different countries yielded consistent results, with annu al incidence rates ranging from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 per 1000 among those aged 70 years or older. 1 Up to 60% of all VTE cases are associated with hospitalization. Pul monary embolism (PE) directly accounts for 5% to 10% of all in hospital deaths and is the lead ing cause of preventable hospital death, ahead of infections. Considering the availability of effec tive VTE prophylaxis, many of these events and deaths could have been prevented. The estimat ed total number of symptomatic VTE events in Poland was ~57 000 DVT cases and ~35 000 PE cases per year.
The long term complications of VTE include recurrent thrombosis, postthrombotic syn drome, and chronic thromboembolic pulmonary hypertension.
Launched in 2014 and held annually on Octo ber 13, the birthday of Rudolf Virchow, a scien tist who developed the concept of "thrombosis" and was a pioneer in the pathophysiology of this disease, the World Thrombosis Day (WTD) aims to increase the awareness of thrombosis among the public, health care professionals, and health care systems.
Key messages for the WTD 2018 are as follows (www.worldthrombosisday.org): 1 VTE is often fatal but many, if not most, cas es are preventable. 2 VTE risk factors include hospitalization, sur gery, cancer, prolonged immobility, family history of VTE, estrogen containing medications (birth control pills or hormone replacement therapy), pregnancy, and/or recent birth. 3 Cancer patients are at a higher risk than the general population of developing serious blood clots. 4 Surgery is one of the risk factors for VTE. While a clot can form after any type of the pro cedure, you are more likely to get one if you have had a major surgery. 5 Family history may increase the risk of VTE and genetic factors can contribute to VTE risk. 6 The signs and symptoms of deep vein throm bosis include pain and/or tenderness in the calf In contrast to an inherited deficiency of AT, PC, and PS, which are very rare in the general population, heterozygous FVL and PTG20210A are common, with the prevalence among Cauca sians of 5% and 2%, respectively. A relative risk of initial VTE increases about 3 to 4 times in subjects with heterozygous FVL or PTG20210A, about 10 times in patients with PC or PS defi ciency, and 10 to 30 times in the case of AT de ficiency.
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10, 11 Interestingly, in contrast to the ini tial VTE episode, a relative risk for recurrent VTE in subjects with inherited thrombophilic defects is only mildly increased and ranges from 1.4 for FVL and PTG20210A to 2.6 for AT deficiency. 11 Testing for thrombophilia should only be per formed when results will be used to improve or modify management. Potential reasons to test for inherited thrombophilia are: 1) identifying thrombophilic defects in asymptomatic fami ly members of patients with VTE and inherit ed thrombophilia to decide on preventive mea sures, for example, not to take an oral contra ceptive; 2) identifying antithrombin deficiency in a patient with resistance to heparin may in dicate the need for antithrombin supplementa tion during an acute episode of VTE; 3) identi fying inherited deficiency of PC or PS may af fect anticoagulation strategy when initiating vi tamin K antagonist (VKA) therapy (risk of skin necrosis); 4) identifying patients who may ben efit from a specific anticoagulant therapy; for ex ample, for patients with highrisk antiphospho lipid syndrome, VKA is probably the treatment of choice; 5) VTE at a young age, particularly if associated with no or weak provoking factors or a strong family history of VTE or recurrent VTE or VTE in unusual sites (eg, cerebral or splanch nic veins) since identification of high risk throm bophilia in such cases may influence the decision on extended anticoagulation. 
rate, and no monitoring) need to be considered against their perceived negative attributes (increased bleeding and drug -drug interactions) and the strength of value that an individual patient gives to each feature. 7 The remarkably complex subject of diagnostics and treatment of antiphospholipid syndrome, as well as of thrombotic complications in hemato logic malignancies, has been presented by 2 lec turers, experts in these fields. Another interest ing issue discussed during the conference was the management of patients with paroxysmal nocturnal hemoglobinuria-the most vicious acquired thrombophilic state known.
Postthrombotic syndrome (PTS) is a chron ic complication of DVT that develops in 20% to 50% of patients. Its overall estimated incidence is 0.7 to 2 per 1000 person years, and increas es with age. 8 The evidence based statement has been recently created by a panel of Polish ex perts with the aim to provide practical recom mendations for the optimal prevention, diagno sis, and management of PTS. 9 Patients with il iofemoral DVT have 2 year PTS rates of 50% or more, despite anticoagulation. These patients are also more likely to develop severe PTS man ifestations, such as disabling venous claudica tion and venous ulcers. Early clot removal can prevent persistent venous obstruction and dam age to the vein valves. Catheter directed throm bolysis (CDT), a direct intrathrombus adminis tration of a fibrinolytic drug via a catheter em bedded within the thrombus, induces a success ful lysis of the thrombus in 80% to 90% of pa tients with DVT symptom duration of less than 14 days. However, 41% of CDT patients still de veloped PTS by 2 years, indicating that CDT does not eliminate the risk of PTS. Pharmacomechan ical CDT (PCDT) involves the use of catheter mounted thrombectomy devices along with in trathrombus delivery of fibrinolytic drugs. It is suggested that CDT/PCDT with or without bal loon angioplasty and stenting migth be consid ered in patients with extensive (eg, iliofemoral) thrombosis with recent onset (ie, ≤14 days) of symptoms, a low risk of bleeding, life expectancy of at least 1 year, and surgical thrombectomy -in patients who are not candidates for PCDT/CDT.
Recent years have brought progress in our understanding of the role of endovascular tech niques (venous bypass procedures and/or stent ing) in the treatment of PTS and the subgroups of patients who may benefit from these modal ities when conservative treatment fails. Intrac table pain, massive edema, progression of skin changes, and venous ulcer formation are among the better justified indications for intervention. Stenting is generally accepted as the treatment for residual deep venous obstructions located between the common femoral vein and inferior
